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Abstract
During the last 20 years, the main clinical effects of vitamin K2 on bone homeostasis
have been investigated in both indirect and direct vitamin K treatment regimens. This
chapter is mainly based on randomized clinical trials (RCT) lasting for more than 1 year.
As for vitamin K1 (phylloquinone, indirect treatment) and vitamin K2 (menaquinone
MK‐4 and MK‐7 direct  treatment),  respectively,  the clinical  trials  have consistently
shown decreased fracture rate incidents, however, mainly in Asian populations. In 2013,
a  major  breakthrough  was  observed  by  Knapen  et  al.  in  the  Netherlands,  where
menaquinone MK‐7 supplementation of 180 μg/day for 3 years to healthy postmeno‐
pausal women significantly decreased the age‐related decline in BMC (bone mineral
contents) and BMD (bone mineral density) at the lumbar spine and femoral neck, but
not at the total hip, as compared to placebo. Thus, MK‐7 supplementation has shown a
significant  “double”‐positive  action  through  (1)  increased  bone  building  and  (2)
decreased bone resorption. We look forward to seeing the clinical effects on low bone
mass and osteoporosis as well as other bone diseases.
Keywords: bone health, RCT trials, vitamin K1, vitamin K2 (MK‐4, menatetrenone),
menaquinone‐7 (MK‐7)
1. Introduction
Vitamin K2 (menaquinone‐4, MK‐4, or menatetrenone) is a very important vitamin K species
serving special functions in several extrahepatic organs, like bone tissue, heart, blood vessels,
kidneys, brain, and cartilage. MK‐4 is a member of a sub‐family with eliciting the same cellular
reactions, but with different effects. MK‐4 is deemed necessary for γ‐carboxylation of proteins,
and activation of the vitamin K‐dependent proteins, i.e., Osteocalcin (bone‐Gla‐protein), matrix‐
Gla proteins (MGPs), Periostin, as well as protein S. Without these activated proteins, the body
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is not able to regulate the process of calcium uptake and bone mineralization. To date, we know
of 19 different vitamin K‐dependent proteins. The process also ensures the access of energy for
a plethora of cellular reactions. The most common of the K vitamins is phylloquinine‐1 (K1). K1
is found in leafy green vegetables, olive oil, and soybean oil, while MK‐4 is found in small
amounts in egg yolks, butter, and hard cheese. Fermented soybeans, known as natto, a special
Japanese food, contain another subfamily member menaquinone‐7 (MK‐7). It is the richest
dietary source of menaquinones (yielding about 1100 μg/100 g). In Western diets, MK‐7 in
fermented cheeses amounts to only 62 μg/100 g, approximately. Very small amounts of MK‐4
are produced by intestinal bacteria. The adequate intake (AI) for vitamin K1 from 2001 in the
United States and Canada was recommended to be 90 μg/day for women, 120 μg/day for men.
These values are based on the need for hepatic vitamin K1 to ensure sufficient clotting factor
synthesis. To date, we know that the early AI is not enough to meet the request for a complete
carboxylation of all the extrahepatic vitamin K‐dependent proteins. When MK‐4 ingestion is
insufficient, the serum concentration of uncarboxylated MGP (ucMGP) or uncarboxylated
Osteocalcin (ucOC) is increased. This serves as the major sign of a deficient intake of K1 or a
deficient hepatic transformation of vitamin K1 to MK‐4. High serum concentrations of MK‐1
and MK‐4 reflect only the recent intake of vitamin K, not the accumulation or steady state levels
of a “chronic” intake. The bioavailability of K1 and MK‐4 is very short, i.e., about 1.5–3 h in
contrast to 72 h for MK‐7. To date, K1, MK‐4, and MK‐7 are available as dietary supplements [1,
2].
Osteoporosis is, on a worldwide basis, the reason for many emerging, spontaneous fractures.
On a global basis, osteoporosis causes more than 88.9 million fractures annually. The condition
is estimated to affect 200 million women worldwide, i.e., approximately one‐tenth of women
aged 60, one‐fifth of women aged 70, two‐fifths of women aged 80, and two‐thirds of women
aged 90 years. Worldwide, one in three women over the age of 50, will experience osteoporotic
fractures, as will one in five of men aged over 50 [3]. From Europe, the number of new fractures
in 2010 was estimated at 3.5 million, comprising approximately 620,000 hip fractures, 520,000
vertebral fractures, 560,000 forearm fractures, and 1,800,000 of other fractures (types or sites).
For women in the EU: approximately 50% of fractures related deaths, were due to hip fractures,
28% to clinical vertebral fractures, and 22% to other types of fractures. In men, the correspond‐
ing figures were 47, 39, and 14%, respectively [3]. From the USA Preventive Services Task Force
(USPSTF) for 2013, it is therefore concluded that the current evidence is insufficient to assess
the balance of the benefits and harm of combined vitamin D and calcium supplementation for
the primary prevention of fractures In the treatment of pre‐ and postmenopausal women or
in men, these indicate that new treatments of osteoporosis are wanted [3, 4].
In 1984, Hart et al. [5] revealed that the serum concentrations of vitamin K1 were very low
among patients with hip fractures, and hypothesized that poor vitamin K status is associated
with increased rates of osteoporotic fractures. The period of 1991–1993 was regarded as the
beginning of the era of vitamin K examinations, since patients‐based studies by Hodges et al.
confirmed that low serum concentrations of vitamin K1 and K2 were associated with increased
risk of spine and hip fracture. The same phenomena were also shown by Szulc et al. in a French
study, yielding a positive association between ucOC and fracture risk [6–8]. Other countries,
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like the Netherlands, as shown by the group of Knaben et al. [9] and Finland, as shown by
Luukinen et al. [10], clearly demonstrated that this association (ucOC versus fracture risk) point
to the fact that vitamin K status is a predictor of bone health (fracture‐free percentage of a
population group). The correlation between low intake of vitamin K and increased fracture
rate was also revealed by prospective analysis within the Nurses’ Health Study cohort 1984.
Here, the diet was assessed in 72,327 women, aged 38–63 years, with a food‐frequency baseline‐
questionnaire. During the subsequent 10 years of follow‐up, 270 hip fractures resulting from
low or moderate trauma were reported. Results: women in quintiles 2–5 of vitamin K intake
had a significantly lower age‐adjusted relative risk (RR: 0.70; 95% CI: 0.53, 0.93) of hip fracture
than women in the lowest quintile [11].
In Japan, a high dose of menaquinone‐4 (MK‐4) of 45 mg/day (15 mg × 3/day) was used as
therapeutic treatment for osteoporosis. The principle cause‐effect of vitamin K2 on osteopo‐
rosis is mainly the prevention of bone fractures due to its improvement of bone quality, and
not the ensuing increasing bone mineral density. Due to variable contents of vitamin K in the
diet, the Japanese Society of Osteoporosis included in 1995 vitamin K2 as Menatetrenone (MK‐
4), together with vitamin D, in the first line treatment of osteoporosis [12].
Osteoporosis, in its primary form, is characterized by bone loss, and the age of females upon
onset or development of menopause, however, the disease also affects a smaller cohort of men.
Genetics is the single most important cause for both sexes, however, changes of lifestyle,
exercise levels, smoking habits, and low body weight, are important contributors, which may
trigger the onset of the disease. Secondary forms of osteoporosis‐related chronic diseases are
rheumatoid arthritis, chronic lung disease, and anorexia. In addition, it is well known that the
use of cortisone or prednisolone can reduce bone mineral density (BMD). Standard examina‐
tion of bone mineral density (BMD) is the dual energy X‐ray absorptiometry (DEXA). BMD
values is not the same for all women and men but different due to race. In the last decade,
research have combined DEXA scan with more specific geometric hip and vertebra measure‐
ments as femoral neck width (FNW) and hip‐axis length (HAL) and vertebral fracture (VF)
assessment (VFA).
However, it may be asserted to a certain extent, that proper bone 3D‐architecture may “make
up” for a marginal reduction in BMD‐values in terms of predictive value of the BMD‐levels
per se.
The incidence of osteoporosis is lower in Japanese women, even though they are subjected to
the same period with menopause as other women. However, in some regions, like in Tokyo,
the intake of vitamin K as MK‐7 in the special fermented food of natto, soybeans together with
other treatments result in higher BMD‐values and lower fracture rates than age‐matched
woman in the United States and Europe [3].
Of other health outcome studies featuring patients with an without osteoporosis, a few warrant
special attention: observational studies of subjects displaying a low long‐term vitamin K intake
revealed a higher incidence of osteoarthritis in the hand and knee [13], dementia [14, 15]. From
population‐based studies of atherosclerosis, Jie et al. revealed that, in atherosclerotic women,
vitamin K status is associated with lower bone mass. All these findings support our hypothesis
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that vitamin K status affects the mineralization processes in both bone and atherosclerotic
plaques in a healthy manner [16]. And, from the population‐based Rotterdam Study, the
relation between low vitamin K status and development of coronary artery disease [17] is
indisputable.
The importance of vitamin D for bone health has been known since it was used in the treatment
of rachitis in the 1930s. Vitamin D and calcium supplements have been recommended as a
pillar in the treatment of osteoporosis over the last three decades. Vitamin D and calcium
supplementation increases spinal BMD in healthy, postmenopausal women [18, 19], and
vitamin D is crucial in the process of mobilizing the Ca2+ ions into the bone tissue [20].
Interestingly, vitamin D and calcium alone are not able to rebuild bone tissue and infrastructure
that are being lost. The synergistic effect of vitamin D and retinoic acid on osteoblast produc‐
tion of osteocalcin was shown in 1993 [21], where Hara et al. demonstrated that MK‐4 was able
to partly inhibit the bone resorption induced by inflammation, vitamin D loss and ensuing
PTH induction, as seen in the calvariae and incubation medium in his mode ex vivo model
system. This observation served later as the basis for the introduction and acknowledgement
of menatetrenone (MK‐4) supplementation in the clinic [22]. And finally, in 1995, Hara et al.
[23] also showed that the inhibition of bone resorption was related to vitamin K2's long side
chain.
2. Vitamin K‐dependent proteins in the bone building process
Osteocalcin is produced by osteoblasts during bone formation, and serves as the most
abundant protein in bone after collagen. Furthermore, it is crucial for bone mineralization.
Activated osteocalcin is located within hydroxyapatite crystals and binds calcium strongly to
facilitate mineralization of the hydroxyapatite crystal grid [24]. Osteocalcin production is
regulated by a plethora of factors including retinoic acid (RA), estrogens, glucocorticoids, as
well as vitamin D [25–27]. In 1995, Douglas et al. showed the percentage of carboxylated
osteocalcin (cOC), as calculated from total osteocalcin, was found to be less than 60% in
osteoporotic postmenopausal women compared to 70–80% in young, healthy adults [28]. The
osteocalcin production is increased by vitamin D but also increased by both MK‐4 and MK‐7
in a synergistic fashion. From 2007, as used by Knapen et al., osteocalcin has been employed
as a marker for the deficiency of vitamin K in bone. Today, the specific osteocalcin molecules
are total Osteocalcin (tOC), ucOsteocalcin (ucOC), and cOsteocalcin (cOC) [28, 44]. A secon‐
dary action of MK‐4 and MK‐7 is the ensuing increased collagen production by cells of the
osteoblastic lineage. Collagen should make the structural fundament, on which calcium and
other minerals are accumulated within the bone matrix. Increased deposition of collagen
makes the bone more flexible and this is very important for the attainment of “higher” or better
bone quality [24]. In 2001, Yamaguchi et al. unraveled the stimulatory effect of MK‐7 on
osteoblastic bone formation in vitro, but they also discovered the suppressive effect of MK‐7
on osteoclast‐like cell formation and osteoclastic bone resorption in rat bone tissues in vitro [29].
Furthermore, in 2001, Yamaguchi and Ma [30] confirmed the dual effects of MK‐7 but also a
significant decrease number of osteoclasts. Finally, in 2011, Yamaguchi and Weilzmann showed
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that MK‐7 reinforces the synthesis of various bone‐specific proteins, mediated through the
pathways of calcium‐dependent protein kinase C signaling, as well as cyclic AMP‐dependent
signaling. MK‐7 also antagonizes the “receptor activator of NF‐κB (RANK) ligand (RANKL)”
induced NF‐κB activation on osteoclast precursors. This concept now makes up the basis for
the search of novel antiosteoporotic medication regimens, mimicking the plethora of effects
induced by MK‐7 [31].
3. Clinical‐related publications featuring K1 supplementation
In relation to the loss of bone associated by deficient intake of vitamin K1, many observational
studies have been conducted. However, few randomized studies have been able to reveal a
significant positive rebuilding of bone mass and increased BMD. This chapter deals only with
randomized clinical trials with a duration exceeding 1 year.
Schaafsma et al. from the Netherlands showed in a 1‐year long randomized study from 2000
[32] (featuring four groups with 400 IU vitamin D3; vitamin K1 supplementation 80 μg daily,
vitamin K1 and D3, and placebo of Dutch postmenopausal women (with a patient total, n =
141) with either normal or low bone mineral densities (BMD). It was shown that women with
low BMD had a lower %cOC at baseline than the women with normal BMD. However, this
difference disappeared after 1 year of supplementation with vitamin K1 [(mean ± S.D.) 68 ± 11%
(95% CI = 64.5 ± 71.2%) versus 72 ± 6% (95% CI = 70.1 ± 72.9%)], respectively. On the other hand,
1 year of supplementation with vitamin D3 showed maximum increases in 25(OH)D of 33
± 29% (95% CI = 24.8 ± 41.8%) and 68 ± 58% (95% CI = 50.1 ± 84.6%) in women with normal and
low BMD, respectively. No effect was observed on BMD [32].
In the Bram et al. study from 2003, three groups were examined; group K1D: the effect of
vitamin K1 (1 mg/day) and vitamin D (8 μg/day including standard mineral supplementation),
group D (vitamin D and minerals) and group 3, placebo on bone loss retardation in a random‐
ized, double‐blind, placebo‐controlled 3‐year intervention study. Of 181 healthy postmeno‐
pausal women between 50 and 60 years of age, 155 completed the observation period. The
main outcomes of the study were significant changes in BMD‐values of the femoral neck and
lumbar spine after 3 years. The group receiving the supplement with additional vitamin K1
showed a decline in the bone loss from the femoral neck. The difference in femoral neck bone
mass between the K1D group and the placebo group was 1.7% (95% CI: 0.35–3.44). The
difference between the K1D group and the D group was 1.3% (95% CI: 0.10–3.41). No significant
differences were observed among the three groups with respect to changes in BMD at the site
of the lumbar spine. It was therefore concluded that the minerals and vitamin D, coadminis‐
tered with the vitamin K1 supplement, substantially contributed to a significant reduction in
postmenopausal bone loss at the site of the femoral neck [33].
In a systematic review and meta‐analysis of 700 patients, Cockayne et al. showed in 2006 that
the MK‐4 intake in Japan yielded a powerful reduction in the incident of fractures. However,
the authors would not recommend vitamin K supplementation until a new randomized clinical
trial confirmed the results [34].
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Boton‐Smith et al. performed a 2‐year, randomized, double‐blind, and placebo‐controlled
study in 2007, scrutinizing the effect of dietary supplementation with either: (1) 200 μg vitamin
K1 daily, (2) vitamin D 400 UI daily (3) and calcium 1000 mg daily, or (4) their combination on
244 healthy nonosteoporotic older women. Baseline and 6‐month measurements included
DXA bone mineral scans of the hip and wrist, markers of bone turnover, and vitamin status.
The results reported were the following: the combined vitamin K1 with vitamin D plus calcium
treatment was associated with only a modest but significant increase in BMC at the ultradistal
radius, however not at other sites in the hip or radius [35].
The Booth et al.'s study was published 1 year later, in 2008. The goal of the present investigation
was to pinpoint the effect of a consecutive 3‐year administration of vitamin K1 on putative
alterations in bone mineral density (BMD) of the femoral neck in elderly patients of both sexes,
who presented upon inclusion with calcium and vitamin D repletion. In the present double‐
blind, controlled survey, 452 individuals (both men and women, 60–80 years of age) were
evenly distributed, in a randomized fashion, each to receive a multivitamin containing either
500 μg/day of vitamin K1 or placebo, in addition to a daily, 600 mg elemental calcium with
vitamin D (400 IU) supplement. Analyses of the femoral neck, spine (L2–L4), and total‐body
BMD, turnover of bone mass, and indigenous status of both vitamins K and D was checked
every 6–12 months. Results were as follows: one could not find any distinction in BMD values
localized to any pertinent body sites, when comparing the two patient groups. Furthermore,
the population receiving the vitamin K1 supplement showed a markedly higher vitamin K1
level, as well as a substantially lower degree (percentage) of ucCO concentrations, when
matched with the patients not ingesting K1. Neither of the additional biochemical variables
measured differed between the patient treatment groups. Hence, the authors concluded that
vitamin K1 supplementation, in a dose attainable in the diet, does not confer any additional
benefit for bone health at the spine or hip when taken with recommended amounts of calcium
and vitamin D [36].
The emerging questions to ask were then: Was the dose of vitamin K1 supplement too low, or
the follow up period too short to elicit an increase of BMD, or was it possible to use other sub‐
family vitamin K members, such as menaquinone‐4 (MK‐4)? Or, could vitamin K supplemen‐
tation potentially be harmful to the body?
Cheung et al. from Canada addressed the last of these questions in their 2–4‐year study from
2008. In this trial, 440 postmenopausal women with osteopenia were randomized into a
placebo‐controlled double‐blind trial, and it was conducted, mainly to determine whether
daily high‐dose vitamin K1 supplementation safely reduces bone loss, bone turnover, and
fractures. The conclusions coming out of the study were: 5 mg of daily vitamin K1 supple‐
mentation for 2–4 years does not protect against age‐related decline in BMD, but may protect
against fractures and cancers in postmenopausal women with osteopenia. Overall fracture rate
was reduced by 50% (9 versus 20, P = 0.04) versus placebo. Interestingly, cancer incidence was
reduced by 75% with vitamin K1 (3 versus 12, P = 0.02). However, more studies are needed to
further examine the effect of vitamin K on fractures and cancers [37].
Brinkley et al. from USA conducted a 1‐year study in 2009 and found that low vitamin K status
is associated with low BMD and an increased fracture risk. From the bulk of reports available
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at that time, it seemed that the menaquinones (menatetrenone: MK‐4), might diminish the
fracture risk incurred by the enrolled patients. Whether vitamin K is an important “by‐player”
in maintaining skeletal health in females situated in the northern part of the US remains an
unsolved issue. Furthermore, different entities of K vitamins (i.e., phylloquinone (K1) and MK‐
4) may exert differing biological effects on the skeleton. The present study was designed to
assess the efficacy of either vitamin K1 or MK‐4 exposure on biomarkers of skeletal health and
bone mineral density (BMD) in postmenopausal nonosteoporotic, North American women. In
the present, placebo‐controlled and double‐blind investigation, a total of 381 postmenopausal
females were given either vitamin K1 (1 mg/day), MK‐4 (45 mg/day), or a placebo treatment.
The whole observation period was 12 months. All enrolled patients/participants were given
either Ca2+ or vitamin D3 supplementation. Bone‐specific BSALP (alkaline phosphatase) in
blood samples, as well as the n‐telopeptide of collagen, type 1 (NTX) were measured at before
the onset of “medication,” and subsequent to 1, 3, 6, and 12 months, respectively. Both lumbar
spine and proximal femur BMD values, as well as proximal femur geometry were assessed by
DXA, before the onset of the trial, and after 6 and 12 months of treatment. At the onset of the
trial, all treatment groups showed identical demographic parameters. The patients’ compli‐
ance rates related to the intake of either calcium, vitamin K1, or MK‐4, were some 87–93%,
respectively. Interestingly, K1 and MK‐4 treatments both diminished the patient levels of serum
ucCO, however, neither BSALP nor NTX levels were changed. Lastly, no effects of K1, or MK‐
4 on lumbar spine or proximal femur BMD or proximal femoral geometric parameters could
be observed. This study does not support a role for vitamin K supplementation in osteoporosis
prevention among healthy, postmenopausal, North American women, receiving calcium and
vitamin D supplementation [38].
4. Clinical randomized controlled osteopenia/osteoporosis studies with
menatetrenone‐4 (MK‐4) from 1 year duration, in countries with different
background intake of vitamin K
In 1998, Orimo et al from Japan evaluated the effects of menatetrenone‐4 (MK‐4) on bone and
calcium metabolism in osteoporosis patients in a 24‐week double‐blind placebo‐controlled
study, where 80 osteoporotic patients were included. Treatment was MK‐4, 90 mg/day (n = 39)
or placebo (n = 41). Bone density was assessed on X‐ray films of the right, second metacarpal
bone, using the microdensitometric method. In the MK‐4 group, bone density increased by
about 2.2 ± 2.5% from the baseline; in the placebo group it decreased by about 7.3 ± 3.7% (P =
0.037, K2 treatment versus placebo). The excretion of γ‐carboxyglutamic acid (Gla) to the urine
was markedly enhanced (i.e., from 72.6 ± 4.1 nmol/mg of creatinine before initiation of
“medication,” to 88.4 ± 5.4 during the 24th week subsequent to the sustained MK‐4 treatment
(P = 0.008) period). In the group receiving placebo, no significant changes in the excretion of
urinary Gla could be observed. However, during the 24‐week long treatment period, the
urinary ratio of calcium over creatinine in the K2 treatment group was reduced from 0.14 ± 0.02
to 0.12 ± 0.02, respectively. However, in the placebo group it increased from 0.15 ± 0.02 to 0.19
± 0.03. Accordingly, the 24‐week levels shown by members of both the MK‐4 and the placebo
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groups turned out to be significantly different (P = 0.03) with unpaired test. Finally, it should
be noted that there were but a few adverse effects, being attributable to the vitamin MK‐4
treatment. One patients increased hepatic enzymes of GOT, GPT, al‐P, and γ‐GTP evaluated
as probable relationship. The results suggest that MK‐4, at a dosage of 90 mg/day, is effective
in maintaining peripheral cortical bone density and is safe in treatment of osteoporosis. The
dose was increased in order to maintaining peripheral cortical density. Interference of diet was
not observed. This study is one of very few, where side effects of the treatment were observed
[39].
In 2000, Shiraki et al. conducted a 2‐year study in Japan, to assess whether MK‐4 effectively
prevented the incidence of new fractures in osteoporotic patients. Two hundred forty‐one
osteoporotic women were enrolled in a 24‐month, randomized, and open label study. The
population constituted: a control group without treatment (n = 121) and an MK‐4 group (n =
120), the latter receiving 45 mg/day. All patients received follow up measurements of lumbar
bone mineral density (LBMD) analyzed by DXA and the occurrence of new clinical fractures
had occurred. Both serum concentrations of Glu‐osteocalcin (Glu‐OC) (RIA, Takara Japan), as
well as MK‐4 were analyzed after termination of the follow‐up period, while both the level of
serum‐OC (RIA, CIS, France) and excretion of deoxypyridinoline (DPD) to the urine were
analyzed prior to and at the end of the treatment. The demographic data of the present groups
did not differ significantly, and the results obtained run as follows: the clinical vertebral
fracture incidence in the control group was 30, compared with 13 in the MK‐4 treated group
(P = 0.027). Furthermore, the percentage change from the initial LBMD value at 6–24 months
after the initiation of the study ranged between −1.8 ± 0.6, and −3.3 ± 0.8% for the control group,
and between 1.4 ± 0.7, and −0.5 ± 1.0% for the MK‐4‐treated group, respectively. The alterations
in LBMD‐values around each measure point turned out to be significantly different, when
comparing the control group with the treated group (P = 0.0010 at 6 months, P = 0.0153 after a
year, and P = 0.0339 after 2 years, respectively). The blood concentrations of Glu‐OC at
termination of the period of observation of the controls and the group receiving active “drug”
were 3.0 ± 0.30 and 1.6 ± 0.10 ng/ml, respectively (P < 0.0001), while blood concentrations of
OC (as analyzed by standard radioimmunoassay (RIA) methodology, gave a marked and
significant rise (42.4 ± 6.9%) over basal value observed in the treated group at 24 months, but
only 18.2 ± 6.1% for the individuals constituting the controls (P = 0.0081)). However, one did
not find any significant change in the amount of DPD excreted into the urine of the treatment
group members. This compilation of information indicates that MK‐4 treatment is effective in
reducing the incidence of additional fractures, even though the MK‐4 treated individuals failed
to show an enhancement of LBMD. Lastly, the study was able to show that MK‐4 treatment
elevates the levels of γ‐carboxylated OC [40].
In 2000, Iwamoto et al. showed in 92 postmenopausal women, aged 55–81 years, completing
a 2‐year randomized controlled trial in four groups receiving either menatetrenone (MK‐4, 45
mg/day), 1α‐hydroxyvitamin D3 (0.75 μg/day), a combination of MK‐4 and D3 (same dosage
as above), or calcium lactate (2 g/day). The MK‐4 and vitamin D3 groups experienced
significant enhancements of their BMD‐values (+0.91 and 0.38%), compared to the “Calcium
group” (–0.79%), while the combined MK‐4 and D treatment, being synergistic, significantly
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increased lumbar BMD by 1.5 %, p < 0.001. These findings indicate that combined administra‐
tion of vitamin D3 and MK‐4, compared with calcium administration alone, appears to be
instrumental in increasing the BMD‐values of the lumbar spine in postmenopausal women
with osteoporosis [41, 42].
Ushiroyama et al. completing a randomized 2‐year study in 2002, investigated the therapeutic
effect of the combined use of menatetrenone MK‐4 and vitamin D3 on vertebral bone mineral
density in 172 postmenopausal women with low bone mass and osteoporosis. Four groups,
each with 43 subjects received the following; either (a) MK‐4, 45 mg/day, (b) standard vitamin
D3 supplement, (c) combined MK‐4 and vitamin D3 therapy, and (d) control group receiving
dietary therapy alone. BMD (bone mineral density) was assessed before initiation of therapy
and subsequent to 6–24 months of treatment, respectively. Analyzed biological markers of
osseous metabolism constituted: serum type 1 collagen carboxyterminal propeptide (P1CP),
intact or total osteocalcin, as well as urinary pyridinoline. Tests for potential of blood coagu‐
lation was done analyzing “activated‐partial‐thromboplastin‐time” (APTT), as well as
assessment of levels of antithrombin III (AT III), fibrinogen, and plasminogen, respectively.
Conclusions summarized in the paper were combined therapy with MK‐4 and vitamin D3
given for 24 months significantly increased bone mineral density = BMD (4.92 ± 7.89%), P <
0.001, but also while MK‐4 alone was significantly enhanced by 0.135 ± 5.44%, P < 0.05. A
majority of the population (77.5%) increased their BMD values, while 22.5% experienced the
opposite. In the MK‐4 group, the marker of bone formation (P1CP) showed an increase by 20%
after 6 months, and while thereafter returning to baseline. Urinary pyridinoline was signifi‐
cantly increased after 6 month, and peaked after 18 months (89.6 ± 112.3%), while slightly
decreasing at 24 months to 53.4 ± 55.7%, P < 0.05. In the combined MK‐4 and D3 group, P1PC
was unchanged for the first 12 months, then it increased at 24 months to 24.2 ± 23.1%, P < 0.05.
Urinary pyridinoline was increased throughout the 24 months to 84.5 ± 51.9%, P < 0.01. The
MK‐4 group at 24 months showed a significant positive correlation between changes of P1CP
and changes of BMD, P < 0.001. In the MK‐4 and D3 groups at 12 months, a significant positive
correlation (P < 0.03) between changes of P1PC and changes of BMD could be seen. In the MK‐
4 and D3 groups, at 12 and 24 months, respectively, significant negative correlations between
changes in pyridinoline and changes in BMD (P < 0.001 and P < 0.004, respectively) could be
observed. The authors conclude that these findings indicate both concomitant enhancement
of net bone formation, as well as some osseous resorption activities. Additionally, observed
significant increments in the coagulation and fibrinolytic reaction pathways were seen.
However, they were both restricted within normal physiological range, suggesting mainte‐
nance of a normalized balance within the fibrinolysis versus coagulation system, since no side
effects were observed [43].
In 2007, Knapen et al. from the Netherlands presented the result of a 3‐year randomized clinical
intervention study of 325 healthy postmenopausal non‐ osteoporotic women receiving MK‐4,
45 mg/day, or placebo. BMC and hip geometry were assessed by DXA, and bone strength
indices were calculated from DXA‐BMD, femoral neck width (FNW) and hip axis length
(HAL). Computations showed that MK‐4 significantly improved the hip bone strength, BMC
and FNW, but in the placebo group, bone strength decreased significantly. However, MK‐4 did
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not affect the DXA‐BMD values. It was therefore speculated that the high vitamin K2 intake
prevented the postmenopausal, nonosteoporotic bone loss. The importance of K vitamins for
optimal bone health has been suggested on the basis of population‐based analyses, however,
intervention trials performed with DXA‐BMD serving as measures of clinical endpoints have
given contradicting conclusions. In contrast, BMC, compared with DXA‐BMD does not take
into account the geometry (size, thickness) of bone, which is construed as an independent
contributor to and “interpreter” of bone resilience and fracture risk [44].
Jiang et al. conducted a 1‐year study in China in 2014. In this randomized, double‐blinded
study, it was evaluated whether the efficacy of MK‐4 is inferior to α‐calcidol in Chinese
postmenopausal women. Two hundred and thirty‐six women were randomized to two groups:
Group MK‐4, receiving 45 mg/day or Group α‐calcidol, receiving 0.5 μg/day, respectively.
Furthermore, all enrolled individuals ingested 500 mg/day of calcium. Assessment of bone
mineral density (BMD) post‐treatment, onset or occurrence of new fractures, as well as serum
OC and ucOC levels were matched with patient baseline values in both patient groups. The
information obtained was as follows: 90.3% of the patients completed the investigation. Results
showed that the BMD‐values in the MK‐4 group significantly increased from baseline by 1.2%
at the lumbar spine, and 2.7% at the trochanter, respectively (P = 0.001). The percentage
enhancement in BMD in the α‐calcidol group and the MK‐4 group was 2.2 and 1.8%, respec‐
tively (P = 0.001). No difference could be seen when comparing either treatment groups. And
one could not spot any alterations in femoral neck BMD between the populations observed.
However, one tibia and one femoral neck fracture in the MK‐4 group, and three lumbar spine
compressive and one forearm fracture in the α‐calcidol group revealed the appearance of new
fractures (P < 0.05). Within the MK‐4 group, the concentration of OC and ucOC, respectively,
fell from baseline levels by some 39 and 82%, respectively (P < 0.001). In the α‐calcidol group,
OC and ucOC fell by some 26 and 35%, respectively (P < 0.001), and the decreases in serum
OC and ucOC were more obvious in the MK‐4 group than in the calcidol group (P < 0.001).
The safety profile of menatetrenone was similar to that of α‐calcidol. It was therefore concluded
that MK‐4 is an effective and safe choice in the treatment of postmenopausal osteoporosis in
Chinese women [45].
Bisphosphonates, combined with vitamin D and calcium are widely used around the world
in the treatment of osteoporotic patients. Vitamin K apparently sustains the lumbar BMD, thus
reducing the incidence of osteoporotic fractures it was natural to investigate and compare
bisphosphonates and MK‐4.
In 2001, Iwamoto et al. presented a 2‐year preliminary randomized study, comparing the effects
of etidronate (E) and MK‐4 on forearm BMD‐values and fracture incidence. Seventy‐two
osteoporotic women, all 5 years after menopause were enrolled. The E‐group received 200 mg/
day, 14 days per 3 months; n = 25, the MK‐4 group received 45 mg/day; n = 23, and the placebo
(C = control group) was given calcium lactate 2 g/day; n = 24. At baseline, there was no
difference between the three groups. Significant results obtained were summarized as follows:
mean percentage change in BMD in the E‐group was a significant increase of 2.1%; P < 0.01. In
the MK‐4 group, it was −0.1%, which was not significant. In the C‐group, there was a significant
decrease in BMD; −1.7%; P < 0.0001. Incidence of new fractures was in the E‐group; total 13
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(nine vertebral and four lumbar), in the MK‐4 group total 10 (seven vertebral and three lumbar),
and in the C‐group; total 12 (seven thoracal and five lumbar). No significant differences could
be spotted between groups. It was therefore concluded that a maintained BMD seen in the MK‐
4 group could be construed as a positive effect, which should be evaluated together with
etidronate treatment [46].
In 2003, Iwamoto et al. examined 98 postmenopausal osteoporotic women in a randomized,
controlled, 2 years study, comprising four groups: (1) MK‐4, 45 mg/day of vitamin K; (2)
etidronate 200 mg/day for 14 days per 3 months; (3) etidronate and MK‐4 combined; and (4)
calcium supplement. End points assessments were: Forearm (distal radius) BMD measured by
DXA using DTX‐200 (Osteometer®), and incidence of vertebral fractures (level T4‐L4). Results
reported are summarized as follows: the forearm BMD in the calcium group was reduced from
baseline, sustained by MK‐4, increased significantly by etidronate, and increased even more
in the MK‐4 and etidronate group. The incidence of vertebral fractures in the MK‐4 group was
8.0%, in the etidronate group 8.7%, in the MK‐4 and etidronate group 3.8%, and in the calcium
group 20.8%, respectively. The compelling conclusion is combined treatment with MK‐4 and
bisphosphonates showed significant different (P < 0.01) between other groups alone. The
author concluded that combined treatment seems to have the greatest efficacy in prevention
of new osteoporotic fractures, and this treatment should be recommended to treat osteoporotic
women [47, 48].
Ishida and Kawai published in 2004 a 2‐year long study, examining 396 postmenopausal
women with osteoporosis, randomized to six equally sized groups: (1) hormone replacement
therapy (conjugated estrogen 0.625 mg/day plus medroxyprogesterone 2.5 mg/day), (2)
etidronate (2 weeks of treatment with 200 mg/day followed by a 10‐week medication‐free
period), (3) ell calcitonin (20 IU/week), (4) α‐calcidol 1 μg/day, (5) MK‐4 45 mg/day, and (6)
control group (i.e., no treatment). End point BMD, bone markers and incidence of vertebral
fractures served as clinically relevant end point measures. The results (2‐year mean changes
in BMD) were 2% for the hormone replacement therapy, −0.5% for the etidronate treatment,
1.6% for the calcitonin treatment, −3.6% for the α‐calcidol treatment, −1.9 for the MK‐4
treatment, and −3.3 for the controls, respectively. Seventeen (26%) of the 66 control patients
developed new vertebral fractures. Compared with controls, the relative risk of incurring
vertebral fractures was 0.35 (95% CI: 0.14–0.83) in the hormone replacement therapy, 0.40 (95%
CI: 0.17–0.92) in the etidronate group, 0.41 (95% CI: 0.17–0.93) in the calcitonin group, 0.56 (95%
CI: 0.26–1.12) in the α‐calcidol group, and 0.44 (95% CI: 0.20–0.99) in the MK‐4 group, respec‐
tively. Hence, the conclusion: a substantial and significant reduction in the incidence of
vertebral fractures was achieved due to either: (a) hormone replacement therapy, (b) etidronate,
or (c) calcitonin medication. Significant improvements in BMD were obtained by the patients
enrolled in the hormone replacement therapy group and in the calcitonin group [49].
Hirao et al. conducted a 1‐year study in Japan in 2008. He enrolled and examined 48 postme‐
nopausal women, but only 44 were followed up after 1 year. This randomized controlled study
consisted of the following groups A, monotherapy of alendronate (5 mg/day) and group AK,
alendronate plus MK‐4 (5 mg/day an 45 mg/day, respectively). The take home message was
clear: MK‐4 decreased undercarboxylated osteocalcin significantly more than alendronate,
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which is known not to influence the degree of carboxylated osteocalcin. In the AK group, the
femoral neck BMD was significantly increased. The small number of patients enrolled, and the
short observation time undermines any conclusion drawn from this study. Further investiga‐
tions using this combination therapy were recommended [50].
Je et al. from Korea published in 2011, a study evaluating the effects of MK‐4 supplementation
on bone mineral density and undercarboxylated osteocalcin (ucOC) in 78 postmenopausal
Korean women 60‐years‐old plus. These women, not receiving any medical treatment, were
randomized into two groups: (1) calcium and vitamin D, n = 40) or (2) vitamin K supplemen‐
tation, n = 38, receiving 15 mg of MK‐4 three times a day after every meal, calcium carbonate
315 mg twice daily, and active vitamin D3, 400 UI once a day. The dosage of calcium and vitamin
D3 was the same in both groups. After 6 months of treatment, the members of the MK‐4 group
showed a decrease in ucOC (−1.6 ± 1.6 ng/dl versus −0.4 ± 1.1 ng/dl) with a P‐value of 0.008.
The vitamin K (MK‐4) group members showed a significant improvement of L3 BMD‐values,
however, no significant enhancement of the BMD‐values in L1, L2, and L4. Similarly, no
significant increase was observed for femoral BMD, which remained unchanged in the women
receiving vitamin D and calcium [51].
In 2012, Fang et al. presented a meta‐analysis of randomized controlled trials published during
the period of 1999−2009. The analysis examined the role of vitamin K on bone mineral density
(BMD). The study revealed that vitamin MK‐4 supplementation was associated with increased
BMD at the lumbar spine, however not necessarily at the femoral neck. This untoward
heterogeneity may be the result, may reside within different participant groups, different
regions of the skeleton, gender, and type of vitamin K1 and MK‐4 supplementation. Hence,
further studies are deemed required to investigate and unravel the detailed effects of vitamin
K2 sub“populations” or metabolites on BMD [52].
5. Clinical randomized controlled studies with menaquinone‐7 (MK‐7)
Japanese menopausal women have traditionally a lower fracture risk than women from the
western world [3]. An association with the ingestion of natto (a processed food containing
fermented beans) was evaluated by Katsuyama et al. [53] and Ikeda et al. [54] in the so‐called
Japanese population‐based osteoporosis (JPOS) study. The dietary natto intake over 3 years
was shown to significantly increase the changes of total hip BMD P < 0.003. The alleged
prevention of postmenopausal bone loss through the effects of MK‐7 is more abundant with
natto than other soybean products. More randomized controlled studies are clearly warranted
to substantiate this contention [54].
The Norwegian study published by Emaus et al. in 2010. features a 1‐year randomized double‐
blind placebo‐controlled study with 334 early menopausal, but otherwise healthy, women. The
patient groups received either MK‐7 (360 μg/day) or placebo. The summary of the present trial
disclosed the following: in the MK‐7 group, serum uncarboxylated Osteocalcin (uc‐OC) was
significantly reduced (from 4.14 to 2.22 ng/ml, respectively). In contrast, carboxylated Osteo‐
calcin (c‐OC) was significantly increased (from 13.5 to 19.1 ng/ml, respectively). However, there
was no statistical difference in bone loss rate between the groups at the “total hip site,” nor at
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any other measurements sites. This was most probably due to the shorter follow‐up time, i.e.,
after only 1 year of MK‐7 exposure [55].
After solid organ transplantations, loss of bone mass often occurs and may cause substantial
health problems. In a study (published in 2010) on such a patients group, Forli et al. from
Norway looked at the effect of MK‐7 on bone mass, measured as BMD of the lumbar spine.
Despite the fact that the impact of MK‐7 on the measured BMD was not conclusive, it was
recommended that further studies over an extended period of time should be conducted. Here,
we refer to the main findings in the study.
This study was the first in organ transplantation, featuring the effect of MK‐7 on bone mass, 1
year after lung and heart transplantation. Postoperatively, 35 lung and 59 heart recipients were
actively treated with MK‐7 in a prospective and longitudinal study, receiving MK‐7 supple‐
ment, 180 μg/day or placebo. The results reported were the following: 1 year after solid organ
transplantation, the difference between MK‐7 and placebo for the lumbar spine (L2–L4) BMD
was 0.028 (SE 0.014) g/cm2, P = 0.055, and for L2 to L4, BMC emerged as 1.33 (SE = 1.91) g/cm2,
P = 0.5. Scrutinizing the lung recipients separately, the difference for BMC was 3.39 g (SE =
1.65), P = 0.048. In the heart recipients, however, observed values were 0.45 (SE = 0.02) g, P =
0.9 subsequent to correcting for measures of baseline values.
In a stepwise linear regression analysis, alterations in the L2‐L4 BMD, controlled for alleged
confounding variables (which include the use of bisphosphonates), significant predictors
turned out to be: (a) organ (if heart = 1, BMD = −0.065 g/cm2 , P = 0.001) and (b) MK‐7 versus
placebo (BMD = 0.034 g/cm2, P = 0.019). It so happened, that insufficient vitamin D status was
frequent, and that PTH (parathyroid hormone) levels were augmented in the MK‐7 group,
indicating a more imminent need for ingestion of vitamin D. In conclusion, it turned out that
12 months of MK‐7 ingestion generally suggests a positive effect on BMD of the lumbar spine,
but with diverging responses in “cardio‐pulmonary” recipients. Thus, the patients’ vitamin D
status would benefit from a closer monitoring during vitamin K supplementation [56].
Knapen et al., the Netherlands, published in 2013 the results of their 3 year study on the effect
of low‐dose MK‐7 supplementation on bone loss in 244 healthy postmenopausal women. The
study was a double‐blind, randomized placebo controlled study, with two groups: (a) active
low‐dose vitamin K2 (MK‐7, 180 μg/day), and placebo. Their main task was to investigate
whether low‐dose MK‐7 supplements beneficially could affect bone health in general.
Secondary to an improved and favorable vitamin K status, MK‐7 ingestion from supplements
should have the possibility to significantly reduced age‐related loss of bone mineral density
and ensuing bone mechanical properties. Hence, low‐dose MK‐7 supplements should conse‐
quently result in preventing bone loss in postmenopausal women. In spite of contradictory
data emanating from trials with vitamin K supplementation on the status of bone health, the
European Food Safety Authorities (EFSA) has accepted the health claim on vitamin K's role in
the maintenance of normal and healthy bone structure. In accordance with EFSA's opinion, it
was clearly demonstrated that a 3‐year high‐dose of vitamin K1 and MK‐4 supplementation
improved bone health after menopause.
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Because of the longer half‐life, bioavailability, and greater potency of the long‐chain MK‐7,
they also measured the effect of low‐dose MK‐7 supplementation on bone health, as reflected
by bone mineral density (BMD) of lumbar spine, total hip, and femoral neck. The assessment
of vertebral fractures was performed using DXA. Furthermore, blood levels of ucOC and cOC
were also analyzed, and the ucOC/cOC ratio functions as an indicator of vitamin K “health”
status. All analyses were performed at baseline, and subsequent to 1, 2, and 3 years of sup‐
plementation, respectively. A carboxylation rate of >50% was achieved during the first year of
treatment, and it was maintained throughout the study period.
The main results obtained were as follows: MK‐7 ingestion significantly enhanced vitamin K
status and decreased the age‐related reduction in bone mass, as well as both BMC and BMD
at the level of lumbar spine and femoral neck. However, total hip BMC and BMD decline could
not be “rescued.” Bone strength also seemed to be favorably affected by MK‐7 ingestion,
significantly decreasing the loss of vertebral height of the lower thoracic region at the mid‐site
of the vertebrae. These results confirm the hypothesis that long term supplementation with
MK‐7 beneficially affects bone health. Whether these results can be extrapolated to other
populations with osteoporosis, needs further investigation [57].
6. Anticoagulation and vitamin K‐antagonist association with loss of
bone mass
The need of vitamin K for the activation of clotting factors is lower than for the activation of
extrahepatic vitamin K‐dependent proteins. This is the plausible reason for deficient rebuilding
of bone mass and increased calcification process in blood vessels. Long‐term use of anticoa‐
gulants, likes warfarin, may potentially lead to the loss of bone, and/or an increased incidence
of osteopenia or osteoporosis with and without fractures. The crucial question then is: What
time span for patients on warfarin medication will suffice for the detection of bone loss?
In an observational study conducted in Japan by Namba et al. 2015, the biomarkers during
warfarin use in a 1‐year follow‐up on 42 patients treated for atrial fibrillation were described.
Twenty‐four patients received warfarin (WF group) and 18 patients received non‐warfarin
treatment (Non‐WF group). Results revealed an increased significant difference in ucOC in
WF the group 10.3 ± 0.8 ng/ml, versus non‐WF group 3.4 ± 0.9 ng/ml, P < 0.01. In cytokines,
RANKL in WF group 0.6 ± 0.1 ng/ml versus non‐WF group 0.4 ± 0.1 ng/ml, P < 0.01. After 1
year, DEXA scan showed no significant different between groups. It was concluded long‐term
use of warfarin might be associated with high risk of osteoporosis but also risk of ectopic
calcification in blood vessels. Further randomized studies are needed to evaluate these
patients [58].
Twenty years ago, clinical observations and research demonstrated that women, taking
warfarin during the first trimester of their pregnancy, gave birth to children with punctate
calcifications in the axial skeleton, proximal femurs, and calcanei. The presumed reason has
since long been that prenatal vitamin K deficiency, induced by warfarin, was the reason for
these calcifications [59].
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Large clinical studies on bone mass have given different results, and in early observation
studies, the evaluation of duration of warfarin use and other patients receiving treatment for
osteoporosis was not included. However, two newer studies showed no further risk on bone
mass of warfarin use in elderly patients: In the first one published by Woo et al. in 2008, in a
large cohort of elderly community‐dwelling men, no association was observed between
current warfarin use and bone mass, bone loss or fracture risk. Although warfarin use was
based upon a single assessment, the findings suggest that current warfarin use in older men
does not appear to have clinically important effects on the skeleton [5, 60].
The second experience was summarized by Misra et al. in 2014, featuring long‐term treatment
of incident atrial fibrillation without prior history of fractures. Long‐term warfarin use was
defined in two ways: (1) warfarin use ≥1 year; (2) warfarin use ≥3 years. Event‐score on warfarin
users and nonusers were created to evaluate the association between long‐term warfarin use
and risk of hip, spine, and wrist fractures separately, as well as combined, using Cox‐propor‐
tional hazards regression models. Among more than 20,000 participants with incident atrial
fibrillation, the hazard ratios (HR) for hip fracture with warfarin use ≥1 and ≥3 years, respec‐
tively, were 1.08 (95% CI 0.87, 1.35) and 1.13 (95% CI 0.84, 1.50).
The conclusion of the present trial was as follows: long‐term warfarin use among elders (i.e.,
>65 years of age) with atrial fibrillation was not associated with any increased risk of osteo‐
porotic fractures and therefore does not appear to necessitate additional surveillance or
prophylaxis [61]. These observational studies have focused on clinical fractures as endpoints
below follow‐up time at 5–10 years, but the thesis that warfarin‐induced clinical fractures was
not confirmed. This may be due to the beneficial effect of MK‐7 on bone mass, which appears
to stay unaffected by the impact of warfarin on vitamin K1, which again reinforces the notion
that vitamin K2 status (measured as ucOC) per se is a good marker of bone homeostasis [58].
7. Chronic kidney disease and loss of bone mass (CKD‐MBD)
The link between increased calcification of vessels and bone complications changes the
definition of CKD‐MBD to better describe the complexity of the syndrome [62]. The link
between osteoporosis and cardiovascular morbidity is well described in postmenopausal
women with intact renal function [63]. In chronic hemodialysis patients, a lower bone volume
is associated with higher coronary calcification scores measured by multislice computed
tomography, reflecting a higher risk of cardiovascular events [64]. This association between
vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease was
also described in 2008 by Toussaint et al. [65]. Furthermore, the mortality of hemodialysis
patients was evaluated in 2003 by Taal et al. among 88 hemodialysis patients over a 3.5 years
follow‐up period. Here, it appeared that mortality was associated with age, Ca‐P product, lack
of transplantation and a low bone mineral density measured at the hip. The leading cause of
death (42.5%) appeared to be related to cardiovascular events [66].
The therapeutic options are few, since many women on renal replacement treatment did not
accept reinstigation of hormone replacement therapy. However, the efficacy of hormone
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replacement was confirmed in a randomized trial in women on continuous dialysis, receiving
hormone therapy (estradiol and cyclic norethisterone) for 1 year. At the end of the study, the
active group showed an increase in bone mineral density at the lumbar spine. This difference
between the active and control group (receiving cinacalcet) was significant at all measure‐
ment sites [67]. Active vitamin D analogs, calcimimetics administration and phosphate‐binders
are widely used to suppress iPTH and thus bone specific alkaline phosphatase, as a marker of
enhanced bone turnover.
Kohlmeier et al. were the first to show an independent association between serum concentra‐
tion of phylloquinone <1.2 nmol/l or less (poor vitamin K status) and an increased risk of bone
fracture in patients with end‐stage renal disease [68]. This observation was confirmed by
Fusaro et al. [69] in 2013, showing that hemodialysis patients treated by warfarin for longer
than 1 year had an increased risk of vertebral fractures, compared with patients not on
warfarin. McCabe et al. enrolling 172, stage 3–5 CKD patients without dialysis treatment,
showed that intake of vitamin K was insufficient in more than 50–60% of individuals on a given
diet, if measures of ucOC were conducted (>20% ucOC), and 97% if evaluation was done by
the prothrombin induced by vitamin K absence‐II (PIVKA‐II) assessment (>2 nmol/l) [70, 71].
After establishment of dialysis as a therapeutic intervention, Cranenburg et al. showed in a
study of 40 chronic hemodialysis patients from 2012 that the dietary intake of vitamin K1 and
K2, in general, was insufficient. This was reflected by analyses of plasma levels of desphospho‐
undercarboxylated (dp‐uc) MGP (matrix‐GLA protein), which was increased over the normal
range by some 82.5% with elevated PIVKA‐II values 3.81.4–12.4 ng/ml, reference value <2 ng/
ml. [72]. Elevated dp‐ucMGP levels suggest insufficient vitamin K2 levels on the vascular site,
while high ucOC reflects insufficient vitamin K2 on bone or osseous sites.
A 6 weeks randomized controlled trial on hemodialysis patients evaluated the response of
biomarkers of vitamin K status (dp‐ucMGP, PIVKA‐II and ucOC) to the ingestion of 45, 135,
360 μg/day of MK‐7. The study confirmed that most patients displayed a functional deficiency
at baseline, and that MK‐7 supplementation decreased dp‐ucMGP and PIVKA‐II. However,
only the highest doses brought about a significant decrease in ucOC [73].
In osteoporosis, the main treatment aims at inhibiting osteoclastic bone resorption. The
osteoclast and osteoblast are functionally tightly coupled, and the mechanism of this reciprocal
link is now very well known. By the discovery of MK‐7, which is able to play a role in the
prevention of bone loss from most sites of the skeleton, there is hope for efficient treatment.
MK‐7 has been shown to stimulate osteoblastic bone formation, as well as suppressing
osteoclastic bone resorption in vitro and in humans, as showed by Knapen et al. [57]. MK‐7
suppresses the activation of NF‐κB signaling pathways in both osteoblasts and osteoclasts.
These treatments have not yet been enrolled side by side with vitamin D analogs in CKD
patients. Unfortunately, vitamin K2 is rare in Western diets, but in CKD patients, vitamin K2
levels are very low due to recommended restriction of potassium and phosphate in the diet.
New trials enrolling CKD and chronic dialysis patients treated with MK‐7 supplementation
are presently being conducted to fully evaluate the effect of MK‐7 on atherosclerosis and bone
mineral density.
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8. Conclusion
In the near future, the dose, bioavailability and potency of the vitamin K2 subfamily member
menaquinone MK‐7, will most probably make it possible to improve on the bone building
process, yielding enhanced bone strength and resilience in several bone‐losing patient
categories, such as those suffering from osteoporosis of different etiologies, and patients
presenting with low bone mass (osteopenia).
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